Two Members of an FDA Advisory Committee Quit After Approval of Controversial Alzheimer’s Drug

(Washington Post) June 9, 2021 – Two members of a Food and Drug Administration advisory panel resigned this week after the agency’s contentious decision to approve an Alzheimer’s drug over the objections of its outside advisers.